Standard therapy for XXXX 1985.

@entity1 @entity3110 @entity5585 @entity8 @entity66 @entity5 @entity3109 @entity3639 @entity1215 @entity378
Numerous clinical trials of chemotherapy for @entity378 conducted throughout the world over the past 4 decades have established 2 basic principles of treatment: effective treatment requires the initial concomitant administration of at least 2 drugs to which the @entity1 's organisms are susceptible; and cure of @entity378 requires that treatment continue beyond the time of sputum conversion and amelioration of symptoms. The treatment of @entity378 was revolutionized in the late 1960s with the introduction of @entity1215 . Shorter regimens of 6-9 months in duration became possible. Scores of trials of short-course chemotherapy have been conducted, and more are planned. The goals of the new treatment regimens are to achieve effective sterilization of the @entity66 in the shortest time possible. A table lists drugs now in use in the US and Canada and gives the usual doses, common side effects, and important interactions among drugs. Chemotherapeutic regimens acceptable for use in the US and Canada are well-defined combinations of drugs which must be regularly administered in the recommended dosages and rhythm for a specific time period. Regimens should be highly effective, i.e., a relapse rate of less than 5%, and have a low risk of toxic effects. Regimens also should be acceptable to @entity1 and applicable on a community-wide basis. The regimens recommended meet these criteria and are backed by well-conducted clinical trails. A 9-month regimen consisting of @entity3109 and @entity1215 throughout, usually supplemented in the initial phase by @entity3110 , @entity3639 , or @entity5585 , is a well-tolerated regimen which will cure virtually all @entity1 with susceptible organisms. The initial daily phase may last 2-8 weeks; the continuation phase may be administered daily or twice weekly. These regimens have an overall bacteriologic relapse rate of between zero and 4%. When 4 drugs -- @entity3109 , @entity1215 , @entity5585 , and either @entity3110 or @entity3639 -- are given under close during supervision during the initial 2 months of daily or "induction" therapy, followed by an additional 4 months of @entity3109 and @entity1215 , the results have been excellent. Where primary resistance to @entity3109 or @entity3639 is suspected, the @entity1 should be placed on 1 of the following 3 regimens: @entity3109 , @entity1215 , and @entity3110 ; @entity3109 , @entity1215 , @entity5585 , and @entity3639 ; or @entity3109 , @entity1215 , @entity5585 , and @entity3110 . Short-course chemotherapy for extrapulmonary @entity378 and chemotherapy of @entity378 in @entity1 are reviewed along with several conditions which affect therapy -- @entity378 during pregnancy, @entity8 , @entity5 and other conditions associated with immunosuppression, and drug interaction.
